Sign inJoin waitlistJoin the waitlist

Carl Gay

Associate Program Director, Research · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

Research · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Medical Oncology
2015–2019
Internal Medicine
University of Texas Health Science Center at Houston
2013–2016
New York University Grossman School of Medicine
2009–2013
New York University School of Medicine
2011
Johns Hopkins University
2005

Research

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Cancer Cell · 2021 · First of 30 authors · 843 citations
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Cancer Discovery · 2018 · 519 citations
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Cancer Discovery · 2018 · 409 citations

Lauren Byers
63 papers
John Heymach
43 papers
Jianjun Zhang
28 papers
Don Gibbons
24 papers
Bingnan Zhang
22 papers · 10 as a fellow
Xiuning Le
17 papers
Anne Tsao
14 papers
Ferdinandos Skoulidis
14 papers
Tina Cascone
14 papers · 1 as a fellow
Yasir Elamin
14 papers
Marcelo Negrao
12 papers
George Blumenschein
11 papers

Grants

Defining Biomarkers and Overcoming Resistance to DLL3-Targeting Immune Therapies in Lung Cancer
National Cancer Institute · R01
PI · $671.7K · University of Tx Md Anderson Can Ctr
2026–2031
Detection and Elimination of Drug Tolerant Persister Cells in Small Cell Lung Cancer
National Cancer Institute · R01
Contact PI · $849.7K · University of Tx Md Anderson Can Ctr
2025–2030

Clinical trials

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2021–2027
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029